Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
dc.contributor.author | Chauncey, Thomas R. | en_US |
dc.contributor.author | Gundacker, Holly | en_US |
dc.contributor.author | Shadman, Mazyar | en_US |
dc.contributor.author | List, Alan F. | en_US |
dc.contributor.author | Dakhil, Shaker R. | en_US |
dc.contributor.author | Erba, Harry P. | en_US |
dc.contributor.author | Slovak, Marilyn L. | en_US |
dc.contributor.author | Chen, I-Ming | en_US |
dc.contributor.author | Willman, Cheryl L. | en_US |
dc.contributor.author | Kopecky, Kenneth J. | en_US |
dc.contributor.author | Appelbaum, Frederick R. | en_US |
dc.date.accessioned | 2011-01-13T19:43:37Z | |
dc.date.available | 2011-01-13T19:43:37Z | |
dc.date.issued | 2010-01 | en_US |
dc.identifier.citation | Chauncey, Thomas R.; Gundacker, Holly; Shadman, Mazyar; List, Alan F.; Dakhil, Shaker R.; Erba, Harry P.; Slovak, Marilyn L.; Chen, I-Ming; Willman, Cheryl L.; Kopecky, Kenneth J.; Appelbaum, Frederick R.; (2010). "Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia." British Journal of Haematology 148(1): 48-58. <http://hdl.handle.net/2027.42/78683> | en_US |
dc.identifier.issn | 0007-1048 | en_US |
dc.identifier.issn | 1365-2141 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78683 | |
dc.description.abstract | Attempts to overcome multi-drug resistance in acute myeloid leukaemia (AML) have been limited by toxicities. To investigate the effect of reducing peak drug levels, we performed sequential phase II studies using continuous infusion daunorubicin and cytarabine without (AD) and then with ciclosporin (ADC) in older patients with AML. Untreated patients (age 56+ years) received daunorubicin (45 mg/m 2 per day for 3 d) and cytarabine (200 mg/m 2 per day for 7 d), both by continuous infusion, without (S0112, 60 patients) and then with (S0301, 50 patients) the addition of ciclosporin. Complete response (CR) rates were 38% on S0112 and 44% on S0301. Fatal induction toxicities occurred in 17% and 12% respectively, arising primarily from infection and haemorrhage. Median overall and relapse-free survival was 7 and 8 months for AD respectively, and 6 and 14 months for ADC. Patients with phenotypic or functional P-glycoprotein had somewhat higher CR rates with ADC than AD, although confidence intervals overlapped. In these sequential trials, continuous infusion AD produced CR rates comparable to those with bolus daunorubicin. The addition of ciclosporin did not cause undue toxicities, produced a similar CR rate, and possibly improved relapse-free survival. Further correlate analyses did not identify a subpopulation specifically benefitting from the addition of ciclosporin. | en_US |
dc.format.extent | 199166 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.subject.other | Acute Myeloid Leukaemia | en_US |
dc.subject.other | P-glycoprotein | en_US |
dc.subject.other | Multi-drug Resistance | en_US |
dc.subject.other | Ciclosporin | en_US |
dc.subject.other | Chemoresistance | en_US |
dc.title | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | University of Washington, Seattle, WA | en_US |
dc.contributor.affiliationother | VA Puget Sound Health Care System, Seattle, WA | en_US |
dc.contributor.affiliationother | Fred Hutchinson Cancer Research Center, Seattle, WA | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, WA | en_US |
dc.contributor.affiliationother | H. Lee Moffitt Cancer Center, Tampa, FL | en_US |
dc.contributor.affiliationother | Wichita CCOP, Wichita, KS | en_US |
dc.contributor.affiliationother | City of Hope National Medical Center, Duarte, CA | en_US |
dc.contributor.affiliationother | University of New Mexico, Albuquerque, NM, USA | en_US |
dc.identifier.pmid | 19821823 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78683/1/j.1365-2141.2009.07919.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2141.2009.07919.x | en_US |
dc.identifier.source | British Journal of Haematology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.